BidaskClub Downgrades Repligen (RGEN) to Sell

BidaskClub lowered shares of Repligen (NASDAQ:RGEN) from a hold rating to a sell rating in a research report report published on Wednesday morning.

A number of other brokerages have also weighed in on RGEN. Citigroup initiated coverage on Repligen in a report on Friday, December 8th. They set a buy rating and a $45.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on Repligen in a report on Tuesday, December 5th. They set an overweight rating and a $42.00 price objective on the stock. Zacks Investment Research lowered Repligen from a buy rating to a hold rating in a report on Wednesday, January 24th. Jefferies Group reaffirmed a hold rating and set a $40.00 price objective on shares of Repligen in a report on Thursday, October 19th. Finally, CL King initiated coverage on Repligen in a report on Monday, November 13th. They set a buy rating and a $41.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $44.38.

Repligen (RGEN) opened at $32.66 on Wednesday. Repligen has a twelve month low of $28.88 and a twelve month high of $46.81. The stock has a market capitalization of $1,432.43, a P/E ratio of 56.69, a PEG ratio of 1.84 and a beta of 0.91.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.04. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The firm had revenue of $36.58 million for the quarter, compared to analyst estimates of $35.69 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. Repligen’s quarterly revenue was up 48.2% on a year-over-year basis. research analysts anticipate that Repligen will post 0.61 earnings per share for the current fiscal year.

In other Repligen news, CEO Anthony Hunt sold 8,970 shares of the company’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total value of $322,471.50. Following the sale, the chief executive officer now owns 83,613 shares of the company’s stock, valued at $3,005,887.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Howard Benjamin sold 12,729 shares of the company’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $35.34, for a total value of $449,842.86. Following the completion of the sale, the vice president now directly owns 36,554 shares in the company, valued at approximately $1,291,818.36. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in Repligen in the third quarter valued at $180,000. PNC Financial Services Group Inc. lifted its position in shares of Repligen by 162.8% in the second quarter. PNC Financial Services Group Inc. now owns 5,635 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 3,491 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new stake in shares of Repligen in the third quarter valued at $241,000. Profund Advisors LLC lifted its position in shares of Repligen by 4.7% in the second quarter. Profund Advisors LLC now owns 6,365 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 286 shares in the last quarter. Finally, Suntrust Banks Inc. lifted its position in shares of Repligen by 4.1% in the second quarter. Suntrust Banks Inc. now owns 7,550 shares of the biotechnology company’s stock valued at $312,000 after acquiring an additional 299 shares in the last quarter. 83.34% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2018/02/08/bidaskclub-downgrades-repligen-rgen-to-sell.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit